Merck News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Orderbuch

Analysen

Historisch

24.06.21	Biotech Stocks Facing FDA Decision In July 2021 (RTTNews)
22.06.21	Merck Says Phase III Keynote-826 Study Of Keytruda In Cervical Cancer Met Primar Endpoints (RTTNews)
22.06.21	AstraZeneca : EU Oks Koselugo For Children With Neurofibromatosis Type 1 & Plexiform Neurofibromas (RTTNews)
17.06.21	MSD Announces Supply Agreement with U.S. Government for Molnupiravir, an Investigational Oral Antiviral Candidate for Treatment of Mild to Moderate COVID-19 (PR Newswire)
17.06.21	MSD Announces Supply Agreement with U.S. Government for Molnupiravir, an Investigational Oral Antiviral Candidate for Treatment of Mild to Moderate COVID-19 (PR Newswire)
09.06.21	Merck Inks Deal With U.S. Government To Supply 1.7 Mln Courses Of Molnupiravir - Quick Facts (RTTNews)
07.06.21	Merck Releases New Data From Late-stage Study Of Clear/Keynote-51 (RTTNews)
04.06.21	AstraZeneca : Late-stage Trial Shows Lynparza Reduces Recurrence, Death In Breast Cancer Patients (RTTNews)
03.06.21	Merck Spins Off Organon (RTTNews)
01.06.21	Sanofi, Merck Announce Availability Of Six-in-one Pediatric Combination Vaccine Vaxelis In The U.S. (RTTNews)
28.05.21	Organon Set To Join S&P 500 (RTTNews)
24.05.21	Merck Gets Positive EU CHMP Opinion For KEYTRUDA Plus Chemotherapy For Gastrointestinal Cancers (RTTNews)
20.05.21	Merck Reports Positive Results From Two Trials Of V114 Phase 3 Pediatric Clinical Program (RTTNews)
13.05.21	Merck Says Phase 3 KEYNOTE-522 Trial Met Dual Primary Endpoint In Patients With Breast Cancer (RTTNews)
06.05.21	Fusion, Merck To Evaluate Fusion's Targeted Alpha Therapy In Combination With Merck's KEYTRUDA (RTTNews)
03.05.21	Merck: Spinoff Organon Expected To Drive Sustainable Growth (RTTNews)
29.04.21	Merck Q1 Adj. Profit Declines (RTTNews)
27.04.21	Merck To License COVID-19 Treatment Molnupiravir To Five Indian Generics Makers (RTTNews)
26.04.21	Merck Aims To Achieve Carbon Neutrality Across Operations By 2025 (RTTNews)
19.04.21	Covid-19 Antiviral Oral Drug Found Effective In Hamster Study (RTTNews)
15.04.21	Merck, Ridgeback Biotherapeutics Update Covid Drug Development Program (RTTNews)
15.04.21	Merck To Discontinue Development Of COVID-19 Drug 'MK-7110' (RTTNews)
08.04.21	Merck Says Phase 3 KEYNOTE-564 Trial Evaluating KEYTRUDA Met Primary Endpoint - Quick Facts (RTTNews)
01.04.21	Merck Completes Acquisition Of Pandion - Quick Facts (RTTNews)
30.03.21	Organon To Acquire Alydia Health For Up To $240 Mln (RTTNews)
30.03.21	Merck: CHMP Adopts Positive Opinion For Updated Label Of KEYTRUDA To Include Data From KEYNOTE-361 (RTTNews)
27.03.21	Biotech Stocks Facing FDA Decision In April 2021 (RTTNews)
24.03.21	Merck Names Caroline Litchfield CFO - Quick Facts (RTTNews)
23.03.21	Merck: FDA Approves KEYTRUDA With Chemotherapy For First-Line Treatment Of Esophageal, GEJ Carcinoma (RTTNews)
17.03.21	Merck Names Frank Clyburn President, Human Health - Quick Facts (RTTNews)
17.03.21	Merck: European Commission Approves Expanded Indication For KEYTRUDA - Quick Facts (RTTNews)
16.03.21	Merck: FDA Grants Priority Review For NDA For Belzutifan - Quick Facts (RTTNews)
16.03.21	Merck Reports Topline Data for Bintrafusp Alfa as Second-Line Monotherapy Treatment in Biliary Tract Cancer (PR Newswire)
01.03.21	Merck: FDA To Review NDA For Gefapixant - Quick Facts (RTTNews)
25.02.21	New Data Presented at ACTRIMS Forum 2021 Indicate MAVENCLAD®-treated RMS Patients Mount Protective Antibody Response to Common Vaccines (PR Newswire)
25.02.21	Merck To Acquire Pandion Therapeutics - Quick Facts (RTTNews)
18.02.21	NKTR Teams Up With MRK, Pfizer Initiates Multiple Myeloma Trial, PCSA On Watch (RTTNews)
17.02.21	Nektar Collaborates With SFJ Pharma For Bempegaldesleukin In Head And Neck Cancer (RTTNews)
17.02.21	AstraZeneca: IDMC Recommends Primary Analysis For OlympiA Phase III Trial (RTTNews)
05.02.21	JNJ Single-shot COVID-19 Vaccine At FDA Altar, KPTI Expands Xpovio's Footprint, OTLK On Track (RTTNews)
04.02.21	Merck Issues FY21 Outlook; Elects Robert Davis As CEO (RTTNews)
04.02.21	Merck Names Robert Davis CEO Effective July 1; Kenneth Frazier To Continue As Exe. Chairman (RTTNews)
01.02.21	Merck Gets Positive EU CHMP Opinion For Expanded Approval Of Keytruda (RTTNews)
26.01.21	Merck Presents Interim Data From Phase 2a Trial Of Treatment For Pre-exposure Prophylaxis (RTTNews)
26.01.21	Merck: European Commission Approves KEYTRUDA For Treatment Of MSI-H Or DMMR Colorectal Cancer (RTTNews)
26.01.21	AZN Rejects Media Reports, MRK Quits COVID-19 Vaccine Work, MRNA Sets Eyes On New SARS-CoV-2 Strains (RTTNews)
25.01.21	Merck To Discontinue Development Of SARS-CoV-2 Vaccine Candidates Based On Phase 1 Study Findings (RTTNews)
20.01.21	Merck : FDA Approves Soluble Guanylate Cyclase Stimulator Verquvo To Treat Heart Failure (RTTNews)
12.01.21	Merck : FDA Accepts For Priority Review BLA For Adult Invasive Pneumococcal Vaccine (RTTNews)
07.01.21	Merck Acquires AmpTec - Quick Facts (RTTNews)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

19.11.24		Schwacher Handel: Dow Jones beendet den Dienstagshandel mit Verlusten
19.11.24		Gute Stimmung in New York: NASDAQ 100 letztendlich im Plus
19.11.24		Schwacher Handel: Dow Jones legt am Dienstagnachmittag den Rückwärtsgang ein
19.11.24		Gewinne in New York: NASDAQ 100 legt zu
19.11.24		Dow Jones-Handel aktuell: So entwickelt sich der Dow Jones aktuell
19.11.24		Schwache Performance in Europa: Euro STOXX 50 zeigt sich zum Handelsende schwächer
19.11.24		Angespannte Stimmung in Europa: STOXX 50 verliert schlussendlich

19.11.24

Schwacher Handel: Dow Jones beendet den Dienstagshandel mit Verlusten

19.11.24

Gute Stimmung in New York: NASDAQ 100 letztendlich im Plus

19.11.24

Schwacher Handel: Dow Jones legt am Dienstagnachmittag den Rückwärtsgang ein

19.11.24

Gewinne in New York: NASDAQ 100 legt zu

19.11.24

Dow Jones-Handel aktuell: So entwickelt sich der Dow Jones aktuell

19.11.24

Schwache Performance in Europa: Euro STOXX 50 zeigt sich zum Handelsende schwächer

19.11.24

Angespannte Stimmung in Europa: STOXX 50 verliert schlussendlich

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Givaudan	3’870.00	1.49 %	K V
Lonza Grp	513.60	1.14 %	K V
Swiss Re	125.25	0.20 %	K V
Holcim	88.46	0.11 %	K V
Kuehne+Nagel Int	210.40	0.00 %	K V
Logitech Intl	68.92	-1.20 %	K V
Part Grp Hldg	1’209.00	-1.47 %	K V
CieFinRichemont	118.90	-1.94 %	K V
Nestle	76.66	-1.94 %	K V
Sonova Hldg	300.40	-5.21 %	K V

Nachrichten zu Merck Co.

Aktien Top/Flop

Merck Peer Group Nachrichten

Meistgelesene Nachrichten